Open Access

3‑Bromopyruvate sensitizes human breast cancer cells to TRAIL‑induced apoptosis via the phosphorylated AMPK‑mediated upregulation of DR5

Corrigendum in: /10.3892/or.2022.8264

  • Authors:
    • Yuzhong Chen
    • Li Wei
    • Xiaojing Zhang
    • Xianfu Liu
    • Yansong Chen
    • Song Zhang
    • Lanzhu Zhou
    • Qixiang Li
    • Qiong Pan
    • Surong Zhao
    • Hao Liu
  • View Affiliations

  • Published online on: August 14, 2018     https://doi.org/10.3892/or.2018.6644
  • Pages: 2435-2444
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Previous studies have indicated that the sensitivity of breast cancer cells to tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL)‑induced apoptosis is associated with the expression of death receptors on the cell membrane. However, drug resistance limits the use of TRAIL in cancer therapy. Numerous studies have indicated that death receptors, which induce apoptosis, are upregulated by the endoplasmic reticulum (ER) stress response. 3‑Bromopyruvate (3‑BP), an anticancer agent, inhibits cell growth and induces apoptosis through interfering with glycolysis. In the present study, it was demonstrated that 3‑BP synergistically sensitized breast cancer cells to TRAIL‑induced apoptosis via the upregulation of death receptor 5 (DR5). Furthermore, we found that the protein levels of glucose‑related protein 78 (GRP78) and CCAAT‑enhancer‑binding protein homologous protein (CHOP) increased following treatment with 3‑BP. The expression of Bax (in MCF‑7 cells) and caspase‑3 (in MDA‑MB‑231 cells) increased following co‑treatment with 3‑BP and TRAIL, whereas the expression of the anti‑apoptotic protein Bcl‑2 decreased. In order to investigate the molecular mechanism regulating this effect, the expression of adenosine monophosphate‑activated protein kinase (AMPK), activated by 3‑BP, was determined. It was demonstrated that phosphorylated‑AMPK was upregulated following treatment with 3‑BP. Notably, Compound C, an AMPK inhibitor, reversed the effects of 3‑BP. Finally, a synergistic antitumor effect of 3‑BP and TRAIL was observed in MCF‑7 cell xenografts in nude mice. In conclusion, these results indicated that 3‑BP sensitized breast cancer cells to TRAIL via the AMPK‑mediated upregulation of DR5.
View Figures
View References

Related Articles

Journal Cover

November-2018
Volume 40 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen Y, Wei L, Zhang X, Liu X, Chen Y, Zhang S, Zhou L, Li Q, Pan Q, Zhao S, Zhao S, et al: 3‑Bromopyruvate sensitizes human breast cancer cells to TRAIL‑induced apoptosis via the phosphorylated AMPK‑mediated upregulation of DR5 Corrigendum in /10.3892/or.2022.8264. Oncol Rep 40: 2435-2444, 2018
APA
Chen, Y., Wei, L., Zhang, X., Liu, X., Chen, Y., Zhang, S. ... Liu, H. (2018). 3‑Bromopyruvate sensitizes human breast cancer cells to TRAIL‑induced apoptosis via the phosphorylated AMPK‑mediated upregulation of DR5 Corrigendum in /10.3892/or.2022.8264. Oncology Reports, 40, 2435-2444. https://doi.org/10.3892/or.2018.6644
MLA
Chen, Y., Wei, L., Zhang, X., Liu, X., Chen, Y., Zhang, S., Zhou, L., Li, Q., Pan, Q., Zhao, S., Liu, H."3‑Bromopyruvate sensitizes human breast cancer cells to TRAIL‑induced apoptosis via the phosphorylated AMPK‑mediated upregulation of DR5 Corrigendum in /10.3892/or.2022.8264". Oncology Reports 40.5 (2018): 2435-2444.
Chicago
Chen, Y., Wei, L., Zhang, X., Liu, X., Chen, Y., Zhang, S., Zhou, L., Li, Q., Pan, Q., Zhao, S., Liu, H."3‑Bromopyruvate sensitizes human breast cancer cells to TRAIL‑induced apoptosis via the phosphorylated AMPK‑mediated upregulation of DR5 Corrigendum in /10.3892/or.2022.8264". Oncology Reports 40, no. 5 (2018): 2435-2444. https://doi.org/10.3892/or.2018.6644